ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / KRMD / earnings
LUNG (38) SKYA (43) STIM (28) APYX (21) ⌘ Pro Terminal →

KORU Medical Systems Inc. (KRMD) Next Earnings Date & Expected ±9.7% Move

$3.05 +2.01% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.06

KORU Medical Systems Inc. (KRMD) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $138.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KRMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, KORU Medical Systems Inc. (NASDAQ: KRMD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $3.05 (+2.01% 1D, market cap $138.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, KRMD ranks #443 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KRMD compare to LUNG and SKYA in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), KRMD carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 62.3%, and ROIC of -28.7%. By comparison, LUNG (Pulmonx Corporation) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $129.1M) and SKYA (SkyAI Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $128.4M). Among the 5-stock peer group, KRMD leads on earnings multiple (N/A) while KRMD leads on capital efficiency (-28.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KRMD?
▼

Per KRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000704440), KORU Medical Systems Inc. generated $41.1M in revenue (+22.2% YoY), -$2.6M in net income, and $462.4K in free cash flow against $28.2M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.06 (+0.17%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 1.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510041
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Cash (10)Whales (4)SEC (16)Macro (5)CEO (6)
Each axis scored 0–20
12M PRICE TARGET CONE-7.5% Base Target
$7 Bull$3 Base$2 Bear
📬 FREE KRMD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KRMD)Realized 20D OHLCV Swing Band: ±9.7%
Deterministic 5-Pillar Attribution (41/100 Composite)
🔍 WHY KRMD SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (39% of score)

Altman Z-Score 8.05 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 1.1% FCF Margin ($462.4K FCF) & 62.3% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
33
Grade E$3.00+1.3% Next Q
Q2 (-2Q)
36
Grade E$3.04+4.3% Next Q
Q3 (-1Q)
38
Grade E$3.17-3.8% Next Q
Current
41
Grade D-$3.05-7.2% Hist 90D α
Trajectory: E (33) → D- (41)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KRMD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KRMD currently carries a cautious 41/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.13) and Max Pain ($3.20) forces dealer call-delta covering toward $6.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KRMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KRMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 41%NO 59%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±9.7% Swing Band

±$0.30 Expected Swing
$2.75 (-9.7%)Spot $3.05$3.35 (+9.7%)
MODEL EARNINGS SETUP GAUGE

KRMD Quantitative Pre-Earnings Setup: 41/100

Trailing EPS: $4.25 • YoY Revenue Growth: 22.2%

Model Bullish Setup (41/100)Model Risk Weight (59/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$41.1M-$2.6M$462.4K62.3%
FY 20242024-12-31$33.6M-$6.1M-$319.7K63.4%
FY 20232023-12-31$28.5M-$13.7M-$4.9M62.3%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KRMD)

  • ✓Walkthrough of KRMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
KRMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.56%▼ DESCENDING CHANNEL
2026-11-03O $3.23H $3.23L $2.99C $3.05VOL 165.2K
RES: $3.30SUP: $2.65SMA50: $3.13SMA200: $3.99
$4.85$4.31$3.77$3.23$2.69RES $3.30SUP $2.65$3.052026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KRMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KRMD Butterfly Map → + Track KRMD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +22.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KRMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KRMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KRMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KRMD)

Health Care Rank #443 of 1015 ⚔️ LUNG vs KRMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KRMD vs. LUNG, SKYA, STIM, APYX)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, KORU Medical Systems Inc. (KRMD) ranks #443 by composite RQD confidence (41/100, grade D-) and #613 by equity capitalization ($138.1M). Within this direct 5-issuer industry benchmark cohort, KRMD leads on earnings valuation at N/A trailing P/E, while KRMD leads on capital efficiency and profitability with -28.7% ROIC and 62.3% gross margin. SKYA currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with KRMD at 41/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KRMD ACTIVE
KORU Medical Systems Inc.
D- 41/100 — 62.3% -28.7% +2.01% $138.1M Benchmark Subject
LUNG
Pulmonx Corporation
D- 38/100 — 74.2% -35.0% -14.14% $129.1M /lung-vs-krmd →
SKYA
SkyAI Inc.
D- 43/100 — -30.0% -35.0% -1.35% $128.4M /skya-vs-krmd →
STIM
Neuronetics Inc.
E 28/100 — 48.5% -35.0% -8.44% $171.4M /stim-vs-krmd →
APYX
Apyx Medical Corporation
E 21/100 — 62.5% -28.9% 0.00% $109.5M /apyx-vs-krmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000704440 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), KORU Medical Systems Inc. (KRMD) reported GAAP revenue of $41.1M (+22.2% vs. FY2024 revenue of $33.6M , and +44.2% cumulative change since FY2023) , GAAP net income of -$2.6M, operating cash flow of $462.4K, and free cash flow of $462.4K (+244.6% YoY). On the balance sheet, KRMD closed FY2025 with $28.2M in total assets against $0 in total debt (Altman Z-Score: 8.05, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $41.1M -$2.6M $462.4K $462.4K $28.2M —
FY2024 (FY) 2024-12-31 $33.6M -$6.1M -$319.7K -$319.7K $27.2M —
FY2023 (FY) 2023-12-31 $28.5M -$13.7M -$4.9M -$4.9M — —

3. KRMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, KORU Medical Systems Inc. (NASDAQ: KRMD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $3.05 (+2.01% 1D, market cap $138.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, KRMD ranks #443 in composite RQD confidence.

How does KRMD compare to LUNG and SKYA in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), KRMD carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of 62.3%, and ROIC of -28.7%. By comparison, LUNG (Pulmonx Corporation) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $129.1M) and SKYA (SkyAI Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $128.4M). Among the 5-stock peer group, KRMD leads on earnings multiple (N/A) while KRMD leads on capital efficiency (-28.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KRMD?

Per KRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000704440), KORU Medical Systems Inc. generated $41.1M in revenue (+22.2% YoY), -$2.6M in net income, and $462.4K in free cash flow against $28.2M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KRMD trading relative to its 50-day, 200-day, and 52-week technical levels?

KRMD last traded at $3.05 (+2.01% on volume of 221,701 shares), positioning the stock -2.56% below its 50-day simple moving average ($3.13) and -23.56% below its 200-day simple moving average ($3.99). Across its 52-week range of $2.86 to $6.61, KRMD sits at the 5.1% percentile with a 14-day RSI of 44.5 (NEUTRAL RANGE) and an implied next-earnings move of ±9.7% ($2.75 to $3.35).

Direct Sub-Reports: KRMD RQD Cockpit KRMD 12M Forecast KRMD Earnings & Move KRMD Dividends & DRIP KRMD Insiders & 13F KRMD Whale Options KRMD Profit Sankey KRMD News & Why
ROARABLE RATING BRIEF • RQD 41/100 (D-) ✓ SEC XBRL & RQD VERIFIED

KRMD — KORU Medical Systems Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

KORU Medical Systems Inc. (KRMD) earns a live Roarable RQD composite score of 41/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $3.05 (+2.01% 1D, market capitalization $138.1M).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of -28.7%, gross margin of 62.3%, operating margin of -7.2%, and free cash flow yield of 0.31%.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 8.05, Piotroski F-Score of 7/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

KORU Medical Systems Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry (per the SEC profile). The profile does not describe its products, customers, or revenue model in source data. Market capitalization is $0.1B. Revenue of $41.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), KORU Medical Systems Inc. (KRMD) reported $41.1M in annual revenue (up from $33.6M in FY2024, +22.2% YoY) and -$2.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($28.5M revenue, -$13.7M net income) through FY2025, KRMD scaled operating cash flow to $462.4K and free cash flow to $462.4K, backed by $28.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 41/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of 0.31% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $2.86 – $6.61 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -7.2% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The sector and industry classification (Health Care; Medical/Dental Instruments) is the only contextual link provided. A prospective investor should note that the absence of mapped dependencies means second-order bottlenecks cannot be identified from the source data.

  • Key Question #1: Can KRMD sustain or expand its -7.2% operating margin and -28.7% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $41.1M and free cash flow of $462.4K, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is KRMD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

KRMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for KORU Medical Systems Inc. (KRMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KRMD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KRMD Bull vs. Bear Conversation Board — What's Your Call at $3.05?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KRMD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KRMD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $3.47 (+16.1%)
📌 Pinned Debate

The balance sheet scores strongest in the rating (Altman Z 8.05, Piotroski F 7/9, Debt/Equity 0.5) and revenue grew from $28.5M to $41.

Picked up a starter position in KRMD in my $100K Virtual Cash book at $2.99. The balance sheet scores strongest in the rating (Altman Z 8.05, Piotroski F 7/9, Debt/Equity 0.5) and revenue grew from $28.5M to $41.1M while the net loss narrowed from -$13.7M to -$2.6M.. Trading inside a $2.86–$6.61 52-week range with 0.31% FCF yield gives solid downside support if Medical/Dental Instruments multiples expand this quarter.

VolSurface_Trader 🐂 BULL

@MultipleCompression Shorting a 4/20 institutional whale-flow stock at $2.99 is dangerous when funds are rotating into Health Care.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $2.36 (-21.1%)
Spot @ $2.99

ROIC of -28.7%, an FCF yield of 0.31%, and a beta of 1.0 with a macro regime fit score of 5/20 leave the stock without cash-generation

Here is the bear case nobody on the bull side wants to address on KRMD: ROIC of -28.7%, an FCF yield of 0.31%, and a beta of 1.0 with a macro regime fit score of 5/20 leave the stock without cash-generation or defensive support, and the rating carries a distribution warning.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%